It’s that time of year. Time to look back as a staff to revisit our favorite UNC School of Medicine and UNC Health Care stories from 2016.
This kind of new brain imaging study could help identify cognitive problems and psychiatric disorders very early and develop appropriate interventions.
UNC Lineberger researchers reported at the San Antonio Breast Cancer Symposium they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.
Less than 50 percent of surveyed teens found it ‘very believable’ that cigars are not a safe alternative to cigarettes, according to a first-of-its-kind UNC School of Medicine study.
By blocking a specific cell signaling pathway in lab animals, researchers reversed signs of chronic immune activation, thereby boosting T-cell recovery and viral suppression.
In preliminary findings presented at the 2016 San Antonio Breast Cancer Symposium, researchers showed that older patients were as likely as younger patients to receive targeted therapy and enroll in therapeutic trials based on their sequencing results.
In a study presented at the 2016 San Antonio Breast Cancer Symposium, UNC Lineberger researchers led by Katherine Hoadley, PhD, reported they developed a model that can predict which triple negative breast cancer patients will respond to chemotherapy.
At this year's San Antonio Breast Cancer Symposium, UNC Lineberger researchers and collaborators shared the outcomes of their investigation into the incidence of brain metastasis after a series of drugs were approved to treat HER2-positive metastatic breast cancer, starting with trastuzumab, also known as Herceptin, in the United States in 1998.
The expansion adds 12 beds to provide care for more behavioral health patients.
The award, made possible through a donation from Lenovo chairman and CEO Yuanqing Yang, recognizes the research achievements of young tenured faculty.
Michelle Brownstein, MD, assistant professor of surgery, has been honored with this year’s H. Fleming Fuller Award, given annually to the member of the medical staff who most embodies Fuller’s lifelong commitment to patient care, teaching and community service.
The drug, called SelG1, also reduced the frequency of pain crises in people with sickle cell disease and reduced the number of days they spent in the hospital.
Researchers discuss Zika virus, transmission, and protection during Tuesday's UNC School of Medicine expert panel and community discussion.
On Saturday Dec. 10, 2016, Harvey’s Aces Celebrity Poker Tournament will be held at the Charlotte Museum of History. Proceeds will be donated to the Angelman Syndrome Foundation Clinic at Chapel Hill and the Harvey Baseball Foundation, two non-profit organizations that former professional baseball player Bryan Harvey helped create.
Matt Ewend, MD, FACS, has been named President of UNC Physicians. In this role, Ewend will oversee the physician clinical enterprise of UNC Health Care, which includes more than 2,400 physicians and 600 Advanced Practice Providers in 450 practices spanning the UNC Physicians Network, UNC Faculty Physicians, and physician practices at UNC Health Care affiliate hospitals.
Robert Hill has been living with HIV for 22 years. Five years ago, he enrolled in a study at the UNC School of Medicine, which was part of Dr. David Margolis’ ‘kick and kill’ strategy for eradicating HIV by flushing it out of hiding with a drug called Vorinostat and killing it with either a vaccine or with immunotherapies.
In honor of World AIDS Day on Dec. 1, we take a look at the trailblazing ‘kick and kill’ method of attacking HIV to cure patients. UNC researchers have been working with GlaxoSmithKline on parallel studies at the UNC Cure Center for 18 months to advance this new method of combating the global epidemic of HIV.
In lab experiments, North Carolina researchers developed the first patch to monitor blood viscosity and release blood thinning medication as needed.
Led by John Buse, MD, PhD, director of the UNC Diabetes Care Center, the clinical research of UNC doctors and the participation of thousands of patients culminates in a new, effective, and safe daily injectable drug to combat type-2 diabetes.
Study led by UNC researchers compared group therapy delivered via online chat to face-to-face group therapy